152
Liberty Leaf Holdings Ltd.
(CSE:LIB) (OTC:LIBFF) (FSE:HN3P)
Liberty Leaf Holdings, which you’ve hopefully learned all about in our last issue of CannaInvestor Magazine Canada, is in the business of acquiring partnership interest in up-and-coming and established companies in the medical and recreational cannabis space. The company has two ACMPR applicants in its portfolio, North Road Ventures, and Just Kush, and is an active partner in Esev Genetics, the world’s first genomic platform for high value crop and advancing medicine and foods plant-derived solutions, and Blox Labs, a boutique technology development company providing software solutions such as Blockchain.
This past summer, the company commenced a clinical trial testing the efficacy of CBDs in relieving canine osteoarthritis, which is a condition that includes hip dysplasia, elbow dysplasia and degenerative joint disease. These medical conditions are common in many dog breeds. The drug trial take place for six to eight months as part of an overall three-year collaborative research agreement with Esev R&D LLC, an Israeli-American research and development company. Liberty Leaf sees the success of these trials as an opportunity to market its proprietary formula to pet treat manufacturers and/or potentially develop and brand on its own. Liberty Leaf is committed to the pet wellness part of the business, and has a doctor of veterinary medicine on its Advisory Board.